Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorVA Office of Research and Development

About this trial

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

Eligibility criteria

Qualifiers

Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)>15/hour with CAHI>5/hour, will be included in the experiments

Disqualifiers

less than 18 years old

pregnant or breastfeeding female

have severe respiratory disease that require to be on oxygen

recent health event that may affect the ability to participate in the study,

Trial design

Treatments tested in this trial

  • Acetazolamide + supplemental oxygen + PAP therapy
  • Zolpidem + PAP therapy
  • Buspirone + PAP therapy

Treatment groups

200 Participants
are divided into 3 treatment groups